Risk and protective factors for leprosy development determined by epidemiological surveillance of household contacts.
Household contacts of leprosy patients are the group with the highest risk of developing the disease, and although many risk or prevention factors have been identified, they have not been employed in leprosy-monitoring programs. This investigation aimed to establish the relative risks or the preventive effects of the presence of BCG vaccination, the Mitsuda test, and the ML-Flow assay. Household contacts (1,396) were monitored for a 5-year period. Twenty-eight contacts (2%) developed leprosy and had their clinical and operational classifications established. All immunological tests were performed, and intradermal BCG vaccination was given after the BCG scar count. Of the affected contacts, 75% developed the disease in the first year, and 71.4% were classified as having paucibacillary forms. Contacts of lepromatous leprosy patients presented a 3.8-fold-higher risk of developing leprosy. BCG vaccination and the Mitsuda test showed a protective effect against leprosy of 0.27 (at least one scar) and 0.16 (>7 mm), respectively, and the positive ML-Flow test indicated a relative risk approximately sixfold higher for occurrence of the disease. All unfavorable combinations of two and three assays generated significant risk values that ranged from 5.76 to 24.47, with the highest risk given by the combination of no BCG scar, negative Mitsuda test, and positive ML-Flow test. We suggest that the BCG vaccination may be given to stimulate Mitsuda test positivity, reducing the patient's risk of developing multibacillary forms. The high significance of these tests may have a great impact on programs to monitor contacts and should be used to improve early detection and treatment.
Goulart
Isabela M B
IM
Leprosy National Reference Center, Clinics' Hospital, School of Medicine, Federal University of Uberlandia, Uberlandia, Brazil. isagoulart@centershop.com.br
Bernardes Souza
Dulcinéa O
DO
Marques
Carolina R
CR
Pimenta
Vânia L
VL
Gonçalves
Maria A
MA
Goulart
Luiz R
LR
D000942:Antigens, Bacterial / Q000097:blood / Q000276:immunology; D001500:BCG Vaccine / Q000627:therapeutic use*; D001938:Brazil / Q000453:epidemiology; D019353:Endemic Diseases; D005191:Family Characteristics; D006017:Glycolipids / Q000097:blood / Q000276:immunology; D006801:Humans; D015994:Incidence; D007918:Leprosy / Q000453:epidemiology* / Q000382:microbiology / Q000517:prevention & control* / Q000635:transmission; D009166:Mycobacterium leprae / Q000276:immunology* / Q000302:isolation & purification; D012307:Risk Factors
D000942:Antigens, Bacterial; D001500:BCG Vaccine; D006017:Glycolipids; C045169:phenolic glycolipid I, Mycobacterium leprae